CD4 and graft versus host disease: Clinical GVHD trials registered in http://clinicaltrials.gov employ in vitro generated iTreg and IL-10, TGFβ-producing CD4+ Foxp3− Treg type 1 (Tr1) cells (NCT01634217: MacMillan; NCT03198234: Roncarolo).